The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor

Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

(2013) Stephan A. Veltkamp et al.   CLINICAL DRUG INVESTIGATION

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study

(2012) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

(2012) Vivian A. Fonseca et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

(2011) Giovanni Musso et al.   ANNALS OF MEDICINE

Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study

(2011) Sreeneeranj Kasichayanula et al.   CLINICAL THERAPEUTICS

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

(2011) Sherwyn L. Schwartz et al.   Diabetes Technology & Therapeutics

Diabetes Mellitus Reduces Activity of Human UDP-Glucuronosyltransferase 2B7 in Liver and Kidney Leading to Decreased Formation of Mycophenolic Acid Acyl-Glucuronide Metabolite

(2010) M. Dostalek et al.   DRUG METABOLISM AND DISPOSITION

Sodium-Glucose Co-Transport Inhibitors

(2010) Joshua J. Neumiller et al.   DRUGS

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY